CD274 and esophageal squamous cell carcinoma: Pembrolizumab and chemotherapy offered superior OS in ESCC patients (with PD-L1 CPS ≥ 10), with a median of 13.9 versus 8.8 months (HR 0.57 [95% CI, 0.43 to 0.75]; p < 0.0001) respectively.